Method for increasing radioresistance in mammals
SUBSTANCE: invention refers to medicine and veterinary science and aims at increasing the radioresistance in mammals. In the period of 12 hours to 20-30 minutes before a radiation exposure and immediately thereafter, 0.11% oil preparation of chlorophyll is introduced into the mammals. Linseed oil is used as an oil base. The preparation is introduced in a dose of 11-12 mg/kg intramuscularly.
EFFECT: method enables increasing the radioresistance and survival rate in the mammals.
1 tbl, 1 ex
The invention relates to the field of biological chemistry, radiobiology and can be used in the practice of medical and veterinary measures at contaminated by radioactive substances to the environment to increase the radioresistance of mammals.
The known method antiradiation protection (patent RF №1662042, IPC A61N 2/08, publ. 09.07.1995 g), namely, that the radioresistance of mice increased by the impact of physical factors on the organism, an animal before irradiation put on 3 to 4 hours in camera, reducing the intensity of the geomagnetic field up to 5·10-10t.
The disadvantage of this method is limited its application to a low degree of increase in radioresistance of the body.
An object of the invention is to increase the resistance and survival of mammals at the various types of radioactive destruction of the organism.
The problem is solved through the use of biological radiosensitive of the drug on the basis of derived natural complex of chlorophylls in the practice of medical-veterinary control and supervision.
The essence of the method lies in the fact that in the period from 12 hours to 20-30 minutes before radiation and after radiation exposure mammals enter 0,11%oil drug chlorophy the La, at the same time as oil is used linseed oil, and the drug is administered at a dose of 11-12 mg/kg intramuscularly.
Studies on drug action of chlorophyll on the survival of mice after ionizing irradiation. The objective of the study was to evaluate the radioprotective action of the drug chlorophyll containing in the molecular structure of magnesium. Also during the experiment, we investigated the toxicity, blood picture, the state of the antioxidant system of the organism.
Chlorophylls (a, b) - according to the chemical nature of the esters of dicarboxylic acids of chlorophyllin and two alcohols methyl and unsaturated monohydroxy alcohol phytyl side-chain. Therefore, according to the chemical nomenclature can be defined as titillatingly: chlorophyll a C55H72O5N4Mg, chlorophyll b - C55H70O6N4Mg.
Pigments absorb visible light, but not all, selectively, i.e. each pigment has its own characteristic absorption spectrum. In particular, the most important feature of the absorption spectrum of chlorophyll a and b have two distinct peaks in the red region, respectively 660 and 640 nm in the blue-violet 430 and 450 nm. The minimum absorption lies in the area of green light. This explains the green color of the pigments. Live leaf at chlorophylls wider and aligned absorption spectrum. So, KRA is hydrated maximum absorption of chlorophyll ain the chloroplast has several peaks: 670, 683, 700, 710 nm; chlorophyll b is for wavelengths 650-655 nm. A similar shift towards the long-wave part is true for the blue max. These differences between the absorption spectra of chlorophylls in solution and the sheet is determined by the degree of aggregation of the molecules of the pigment and the nature of their connection with lipoproteidnyi complex in the leafs of the thylakoids.
Chlorophyll b differs from chlorophyllaonly substitution at the third carbon atom in the second pyrrole ring in its molecule the methyl group PA aldehyde. In General, a molecule of chlorophyll due to structural and physico-chemical features able to perform three major functions: to selectively absorb light energy; to store it in the form of electronic excitation energy; photochemically convert the energy of the excited state in chemical energy primary fotovosstanovlenii and vodoochischennya connections.
On the production facilities of LLC "Limex-Pharma" (Moscow) was produced from vegetable raw materials of plant pigment chlorophyll. For experiments, we studied 0,11%drug chlorophyll in solution of linseed oil. Before applying the oil, the drug was dispensed in vials of 20 ml, for sterilization added streptomycin sulfate.
The study of radioprotective is waist conducted pas outbred mice in the amount of 100 heads. Teams were formed: control and test subjects. Animals of both groups were subjected to a single total uniform exposure to gamma radiation from Cs-137 at the "Panorama" with the power 4,3 R/min doses 12,18 Gr (1400 R). The drug was administered intramuscularly in a volume of 0.2 ml (11-12 mg/kg). Was also taken control of irradiation with linseed oil, used for dissolution of chlorophyll. Experimental animals were divided into groups, which were injected oil drug chlorophyll before and after irradiation:
1) the introduction of the drug for 12 h before irradiation;
2) the introduction of the drug for 20-30 min before irradiation;
3) the introduction of the drug in 15-20 min after irradiation;
4) the introduction of the drug for 20-30 minutes before and after 15-20 min after irradiation;
5) the introduction of the drug for 20-30 minutes before and after 15-20 min after irradiation and on the 5th day;
6) the introduction of the drug in 15-20 min after irradiation and on the 5th day;
7) introduction of linseed oil for 12 hours before irradiation;
8) introduction of linseed oil for 20-30 min before irradiation;
9) introduction of linseed oil in 15-20 min after irradiation;
10) control (drug did not enter).
The survival rate of mice at the dose of 1400 R (12,18 Gr) are presented in table 1.
In parallel with the test under irradiation was tested toxicity of the drug and oil on linen 10 outbred white mice-males. The preparation of chlorophyll was in the Eden intramuscularly at a dose of 0.2 ml Survival to 30 days 100%. Vegetable oil was given intramuscularly at a dose of 0.2 ml of Survival to 30 days 100%.
The main indicators of the effectiveness of the drug chlorophyll served the survival of animals within 30 days after irradiation, the lifespan of mice.
The study of the acute toxicity and the pyrogenic action of the drug chlorophyll was carried out in the laboratory of preclinical research Institute of environmental medicine of the Kursk state medical University.
The results of the research. Absolutely lethal dose for mice is dose 7,83 Gr (900 R).
The results of the study of radioprotective properties of the drug chlorophyll presented in table 1.
Survival to 30 days in group 2 (introduction chlorophyll 20-30 minutes before exposure) reached 40%, with a lifespan of up to 68 days, compared with control - 7 days.
Survival to 30 days in group 4 (introduction chlorophyll 20-30 minutes before and immediately after irradiation) reached 20%, with a lifespan of up to 71 days, compared with control - 7 days.
It is noteworthy that in the group of 8 (introduction linseed oil for 20-30 minutes before exposure) and group 9 (introduction of linseed oil in 15-20 min after irradiation), which was used to control exposure with linseed oil, the survival rate of mice SOS is Avila 10% and 10%. The survival rate of the control group 10 was 0%.
In General, evaluating the "work" derived porphyrin - chlorophyll in the "beyond" radiation doses, it should be noted that its use increases the lifespan of mice in comparison with control, effective application to radiation and after radiation exposure.
A comparative clinical study of acute toxicity derived porphyrin - chlorophyll found that intramuscular and intragastric administration maximum dose (3 g/kg) for these routes of administration in mice, the drug does not cause toxic effects. The drug chlorophyll can be attributed to low-toxic drugs.
In the study of pyrogenic reactions in response to intramuscular injection of chlorophyll found that the drug does not cause a statistically significant relative to control group increased body temperature.
The proposed method is experimentally demonstrated that isolated from plant materials preparation chlorophyll has a pronounced radioprotective property in excess of the lethal doses of radiation. Effective when applied before irradiation and after irradiation.
According to the report of the state educational institution of higher professional education "Kursk state medical supply is a ski University from 17.12.2010, "On pre-clinical study of acute toxicity and pyrogenic actions of drugs curcumin (PPL-12K) and chlorophyll (PPL-17TH) production LLC LIMEX-PHARMA" (Moscow)" the drug chlorophyll refers to malotoksicen drugs.
|Group||Qty (PCs)||Survival||Time (day)|
|Continuation of table 1|
The method of increasing the resistance of the organism mammals in the radioactive defeat, namely, that in the period from 12 hours to 20-30 minutes before radiation and after radiation exposure mammals, e.g. the Yat 0,11%oil preparation chlorophyll, at the same time as oil is used linseed oil, and the drug is administered at a dose of 11-12 mg/kg intramuscularly.
FIELD: medicine, pharmaceutics.
SUBSTANCE: composition for treating oxidative stress comprises ball-shaped lipoic acid or one of salts thereof, and at least one lipophilic medium. The lipoic acid balls represent particles consisting of an inert core (a nucleus) coated with lipoic acid which is coated with a first layer of an isolating polymer, and with a second polymer layer resistant (stable) at gastric pH. What is also described is a preparation for treating oxidative stress with an unified dose containing the above composition. The preparation is presented in the form of a soft gelatin capsule.
EFFECT: compositions according to the invention are stable in the lipophilic medium.
22 cl, 15 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, particularly toxicology and radiology, to drug preparations based on antioxidant proteins and methods of using them. The pharmaceutical composition for treating toxic conditions wherein the therapeutic effect is ensured by the action of antioxidant, antimicrobial, antitoxic human lacroferrin protein on the human body contains non-replicating nanoparticles of human adenovirus serotype 5 genome with inserted human lactoferrin expressing human lactoferrin in the therapeutically effective amount in the body, and an expression buffer with the particle content not less than 2.33×1011 of physical particles per ml of the expressing buffer. The method of therapy involves administering the composition in the therapeutically effective dose of 7×1011 of physical particles to 7×1013 of physical particles per ml of the expressing buffer per an individual; the composition is administered intravenously.
EFFECT: invention provides the stable therapeutic effect after the single administration of the composition.
17 cl, 14 ex, 4 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for the therapy of acute toxic conditions. The composition for the therapy of acute toxic conditions contains a protein - human lactoferrin, and additionally contains non-replicating nanoparticles with an inserted gene of human lactoferrin, and an expressing buffer in the following proportions per a dose: human lactoferrin 50 to 100 mg; non-replicating nanoparticles - 7×1011 of physical particles; the expressing buffer - the rest, ml. Human lactoferrin is either donor breast milk lactoferrin, or any human lactoferrin.
EFFECT: invention provides fast onset and prolonged antitoxic action.
4 cl, 8 ex, 2 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmacy and can be applied in production and application of solutions for intravenous introduction in treatment of conditions, associated with endogenous intoxication. Disintoxication solution contains components in the following ratio (wt %): sodium hypochlorite 0.04-0.08, sodium chloride 0.50-1.00, aminoethane sulfonic acid 0.02-1.20.
EFFECT: novel infusion solution is claimed.
4 ex, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely an agent possessing anti-inflammatory action. The agent possessing anti-inflammatory action contains as active ingredient in the form of a complex prepared of a coelomic fluid of sea urchins containing peptides and amino acids at a certain ratio of the ingredients.
EFFECT: agent possesses a manifested anti-inflammatory effect.
2 cl, 2 tbl, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a method for preparing a carbon sorbent with the antibacterial properties, and to the carbon sorbent with the antibacterial properties prepared by this method. The declared method involves impregnation of the carbon hemosorbent granules in an initiator solution in N-vinylpyrrolidone at pH 7.0-7.5 and a residual pressure of 15-20 mm Hg. The hemosorbent : initiator solution in N-vinylpyrrolidone ratio is 1:1.4-2.0. Then the temperature is raised to 65-75°C, kept at that temperature for 0.5-8 hours in an inert medium and washed in water from the residual monomer at room temperature.
EFFECT: carbon sorbent with the antibacterial properties prepared by the specified method represents the round granules, contains polyvinylpyrrolidone in an amount of 4,5-5,5% and is characterised by a specific surface adsorption of less than 50 m2/g and total pore volume of less than 0,30 cm3/g.
2 cl, 2 tbl, 1 dwg, 7 ex
SUBSTANCE: invention refers to medicine and aims at treating necrotic ulcers of oral mucosa in patients with multiple myeloma. Luminal-dependent chemiluminescence of oral fluid is conducted to determine fluorescence light sum and maximum flash. If the light sum value is within the range of 1.02 to 6.6 standard units, and the maximum flash value is 0.7 to 2.5 standard units, the toothpaste Lacalut fluor is used 2 times a day and solcoseryl dental adhesive paste 4 times a day after meals and before bedtime to relieve symptoms completely. The light sum value 8.3 to 13.5 standard units and the maximum flash value 3.4 to 4.2 standard units, the toothpaste Colgate total propolis is used 2 times a day and the film preparation Oblecol three times a day to relieve symptoms completely.
EFFECT: use of the invention reduces a length of epithelisation of necrotic ulcers of oral mucosa.
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is using water-soluble hybrid macromolecular compounds O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl-(1→6)-α-D-glucan and polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as erythroprotective agents for phenylhydrazine poisoning. It is shown that the course intravenous introduction of the compounds has manifested erythroprotective action.
EFFECT: invention extends the range of agents applicable in integrated therapy of phenylhydrazine poisoning.
1 tbl, 3 ex
SUBSTANCE: invention refers to medicine, particularly, the use of human lactoferrin apo-form as an antihypoxant and a hypoxia inducible factor-1 alpha stabiliser.
EFFECT: invention provides the use of the natural iron chelator lactoferrin, no toxicity, hypoallergenicity, an ability to penetrate through the bowel into the blood flow and through the blood-brain barrier.
2 tbl, 1 dwg
SUBSTANCE: method involves the introduction of lead acetate and a calcium-containing substance. For this purpose, 10% calcium chloride 0.3 ml per 200 g is introduced in rats once a day daily through a probe into a stomach for 20 days. In 4 days from the beginning of the experiment, it is combined with the subcutaneous introduction of lead acetate 40 mg/kg at a metal basis for 16 days.
EFFECT: method is easily reproducible, cost-saving and moreover provides relieving toxic action of lead effectively.
5 tbl, 2 dwg, 1 ex
SUBSTANCE: there are presented: a method of treating a disorder associated with the exposure to an alkylating agent specified in a group: sulphur mustard, nitrogen mustard, chlorine gas, 2-chlor-ethylethylsulphide and phosgene gas by introducing an effective amount of tetrakis-N,N-diethylimidazolium porphyrine or a pharmaceutically acceptable salt, particularly AEOL-10150, and a respective method for protection of an individual against toxic effects related to the exposure to the above alkylating agents. The porphirin AEOL-10150 analogue, a free radical acceptor MnTbap keeps the cell viability unchanged in the similar environment.
EFFECT: what is shown is achieving the declared applications: prevention of the organ disorders, and organ recovery following the exposure to sulphur mustard.
15 cl, 15 dwg
SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating acute epididymo-orchitis. With underlying antibacterial therapy, a photodynamic therapy (PDT) is applied by intravenous administration of the photosentitiser "Photolon" 1-1.5 mg/kg. The patient is irradiated intravenously for 10 minutes, and then locally - for 5 minutes. Wave length of the laser radiation is 662±3 nm; radiation power is 1-2.1 Wt in an exposition dose of 60 J/cm2.
EFFECT: method enables the short reduction of the acute process with underlying reduced amount of the applied antibacterial therapy, as well as preserves the reproductive function.
SUBSTANCE: invention refers to medicine, namely to gynaecology, and may be used for treating dystrophic diseases of the vulva by photodynamic therapy. That is ensured by intravenous administration of Photoditazine 0.8-1.0 mg/kg, and 90-120 minutes later, it is followed by the unanesthetised light exposure on the area of the vulva in a continuous mode by a LED apparatus at wave length 660 nm. A dose of the supplied light energy is 180-250 J/cm2 for a total length of light exposure of 30-50 minutes. If the clinical symptoms of the disease appear to be persistent, the photodynamic therapy is repeated to achieve a positive therapeutic effect. With a large area of abnormality, the vulva area is divided into quadrants that are consistently exposed to light.
EFFECT: method provides a highly effective minimally invasive, organ preservation method of treating dystrophic diseases of the vulva, which provides a complete recovery of the disease; it is not accompanied by side effects, enables reducing the length of treatment, ensuring the treatment in an outpatient setting.
3 cl, 3 ex
SUBSTANCE: described is a novel meso-tetra[1-(4'-bromobutyl)-3-pyridyl]bacteriochlorin tetrabromide of formula as a photosensitiser for photodynamic therapy (PDT).
EFFECT: low phototoxicity, high photo-induced anti-tumour activity for further use thereof in PDT.
1 cl, 6 ex, 3 dwg
SUBSTANCE: present invention refers to a boron-containing compound of formula: wherein R1, R2, R3 and R4 independently mean -NO2, halogen or a substitute presented by the following formula wherein the substitutes Y are independently found in an ortho-, meta- or para- position on a phenyl ring, and independently mean hydrogen or a substitute presented by formula : provided at least one of R1, R2, R3 and R4 means a substitute presented by formula (2) wherein Y is presented by formula (3); wherein: X means oxygen or sulphur; R10 and R11 are independently specified in hydrogen and C1-C4 hydrocarbonyl; Z means a carborane cluster containing at least two carbon atoms and at least three boron atoms, or at least one carbon atom or at least five boron atoms in a frame structure; r means 0 or an integer within 1 to 20; a means an integer within 1 to 4; and also provided at least one of R1, R2, R3 and R4 means a substitute presented by -NO2 or halogen; and M means either two hydrogen ions, or a two-valence metal ion, a three-valence metal ion, a four-valence metal ion with a charge of the porphirine-metal complex formed by the three-valence or four-valence metal ion being neutralised by a corresponding number of counteranions, dianions. There are also presented a method for visualising a tumour and surrounding tissues, and a method for bimodal therapy of cancer.
EFFECT: invention provides preparing carboranylporphyrines with a prolonged tumour time selectively targeted on tumour cells and destructing them with minimal involvement of healthy tissues.
24 cl, 4 tbl, 12 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to quaternary ammonium salts of meso-tetra[1-(4'-bromobutyl)-3-pyridyl]bacteriocholine of general formula where
EFFECT: compounds possess high photoinduced activity and may be used for the photodynamic therapy of malignant growths as a photosensitiser.
SUBSTANCE: invention relates to medicine and can be used for photodynamic therapy of intraocular neoplasms. For this purpose photosensitiser chlorine e6 monoethylene diamine monoamide adipinate is introduced intravenously in dose 0.4 mg/kg during 10 minutes. 60 minutes after finishing intravenous introduction of PS, fluorescent diagnostics of PS accumulation in neoplasm is started. Intensity of PS fluorescence in intraocular neoplasm is controlled. When maximal fluorescence of neoplasm in comparison with surrounding tissue is achieved, neoplasm is irradiated transpupillarily with laser radiation. Wavelength corresponds to maximum of luminous radiation absorption by photosensitiser.
EFFECT: method makes it possible to perform treatment of intraocular neoplasms of small and medium size, reduce dose of introduced preparation and density of laser radiation energy, accelerate complete tumour regress due to higher PS tropism by tumour cells.
3 cl, 3 dwg, 2 ex
SUBSTANCE: photosentitiser photosense 0.3-0.4 mg/kg is administered intravenously into a patient. Then 2-3 hours later, a tumour and surrounding skin are exposed to a circular field of laser tele-irradiation at the distance of min. 3 cm at wave length 670 nm, single light dose min. Ws 50 J/cm2 and power density Ps 40÷50 mWt/cm2. Thereafter, a tumour diameter is exposed to the circular field at single light dose Ws 100÷200 J/cm2 and power density Ps 100÷200 mWt/cm2. After a pause of 24 hours, irradiation of the same mode is added with contact irradiation generated from 2-3 positions and covering the tumour and border skin at light dose W 100 J and light guide output power P 200÷250 mWt in each position.
EFFECT: method enables the effective therapeutic management of the patients with stages 1-2a-3a primary skin melanoma, provides avoiding surgical interventions requiring general anaesthesia, makes it possible to treat the patients with manifested cardiac, pulmonary and other comorbidities if observing contraindications for surgical management and general anaesthesia, allows outpatient care, reduces length of treatment and medical rehabilitation, minimises post-treatment complications.
SUBSTANCE: polycrystalline silicon powder with mean grain size of about 5 mcm is put into a chemical etching solution consisting of a mixture of hydrofluoric and nitric acid and water in ratio 2:1:10, and held therein for 60-90 minutes while stirring continuously until the end of porosification of silicon. The powder of porous silicon is then filtered, dried for 30 minutes at temperature of about 100°C and mixed with a solution of a photosensitiser from the class of cyclic tetrapyrroles with concentration from 5×10-5 to 3×10-3 mol/l. The obtained suspension is filtered and dried on air.
EFFECT: obtaining a novel hybrid photosensitiser, which widens the range of agents for action on cancer cells through photodynamic therapy.
1 dwg, 2 ex
SUBSTANCE: invention refers to medicine, dentistry, and is applicable for preventing and treating dental diseases of teeth and oral cavity. For this purpose, a surface of gums and teeth is exposed to an optical range, and the exposure is combined with tooth brushing with using a tooth paste. The tooth brushing is combined with exposure of the oral mucosa opposite to the teeth. The tooth paste is presented by a tooth paste with a photosensitiser. Wave length of the emission directed to the teeth is specified to be close to the wave length of photosensitiser excitation. Wave length of the emission directed towards the oral mucosa opposite to the teeth is specified in a short-wave optical spectrum.
EFFECT: method provides improved antimicrobial, anti-inflammatory, anti-caries action ensured by stimulation of cell restoration processes, improvement of local tissue circulation and nutrition, relieved oral irritation and inflammation.
5 cl, 1 dwg
SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.
EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.
3 cl, 5 dwg